Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis & W.K. Buckley

This article was originally published in The Tan Sheet

Executive Summary

Novartis is "currently evaluating the opportunity of expanding" Buckley's cough/cold line in U.S. in wake of marketing, distribution deal between the two companies. Toronto-based firm's top-selling Buckley's Mixture cough syrup trades on its "tastes awful and it works" claim and has been sold in U.S. since 1930s; firm launched a $2.1 mil. North American ad campaign three years ago (1"The Tan Sheet" Aug. 16, 1999, p. 5). Buckley's line rounds out Novartis' Canadian cough/cold offerings, which include Triaminic syrups for children, NeoCitran hot liquid powder, Otrivin nasal spray. Companies announced "innovative" agreement Nov. 15 that provides Novartis with "exclusive and indefinite rights to sales, marketing and distribution of Buckley's products throughout the world," according to Novartis...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS094856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel